史鲁斌,范张洁,杜冰会

• 1:带状疱疹疫苗常见不良反应识别与处理共识编写专家组
• 2:河南省疾病预防控制中心
• 3:郑州市疾病预防控制中心

摘要(Abstract)：

接种带状疱疹疫苗是预防带状疱疹及其并发症的有效手段。带状疱疹疫苗具有较好的安全性，但因为疫苗本质的因素、受种者个体差异及接种操作等原因，少数受种者接种后可能会出现预防接种不良反应。本共识针对接种带状疱疹疫苗后可能出现的不良反应，重点阐述了其识别及处理方法。通过这份专家共识，希望能为预防接种工作者在处理带状疱疹疫苗不良反应时提供参考，同时提高公众对带状疱疹疫苗安全性的认识，增强接种信心。

关键词(KeyWords)： 带状疱疹疫苗;预防接种不良反应;临床处理;专家共识

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关计划项目（RKX202002006）

作者(Author): 史鲁斌,范张洁,杜冰会

DOI: 10.13515/j.cnki.hnjpm.1006-8414.2024.08.001

参考文献(References)：

• [1]李兰娟,任红.传染病学[M].9版.北京:人民卫生出版社,2018:88-89.
• [2]于生元,万有,万琪,等.带状疱疹后神经痛诊疗中国专家共识[J].中国疼痛医学杂志,2016,22(3):161-167.
• [3]中国医师协会皮肤科医师分会带状疱疹专家共识工作组,国家皮肤与免疫疾病临床医学研究中心.中国带状疱疹诊疗专家共识(2022版)[J].中华皮肤科杂志,2022,55(12):1033-1040.
• [4]中国医疗保健国际交流促进会皮肤科分会,中华医学会皮肤性病学分会老年性皮肤病研究中心.带状疱疹疫苗预防接种专家共识[J].中华医学杂志,2022,102(8):538-543.
• [5] LECRENIER N, BEUKELAERS P, COLINDRES RR, et al.Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention[J].Expert Rev Vaccines,2018,17(7):619-634.
• [6] LEVIN MJ, WEINBERG A. Immune responses to zoster vaccines[J].Hum Vaccin Immunother,2019,15(4):772-777.
• [7] DIDIERLAURENT AM, Laupèze B, DI PASQUALE A, et al.Adjuvant system AS01:Helping to overcome the challenges of modern vaccines[J]. Expert Rev Vaccines, 2017,16(1):55-63.
• [8]宁桂军,殷大鹏.世界卫生组织关于水痘和带状疱疹疫苗的立场文件(2014年6月)[J].中国疫苗和免疫,2014,20(6):562-567.
• [9] HALES CM, HARPAZ R, ORTEGA-SANCHEZ I, et al. Update on recommendations for use of herpes zoster vaccine[J].MMWR Morb Mortal Wkly Rep,2014,63(33):729-731.
• [10] TRICCO AC, ZARIN W, CARDOSO R, et al. Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged50 and older:Systematic review and network meta-analysis[J].BMJ,2018,363:k4029.
• [11] MCGIRR A, WIDENMAIER R, CURRAN D, et al. The comparative efficacy and safety of herpes zoster vaccines:A network meta-analysis[J].Vaccine,2019,37(22):2896-2909.
• [12]高语嫣,孙昊,闫威等.北京市东城区≥50岁人群带状疱疹疫苗上市后不良反应主动监测[J].中国疫苗和免疫,2022,28(3):350-355.
• [13] HESSE EM, SHIMABUKURO TT, SU JR, et al. Postlicensure safety surveillance of recombinant zoster vaccine(Shingrix)-United States, October 2017-June 2018[J].MMWR Morb Mortal Wkly Rep,2019,68(4):91-94.
• [14] TAVARES-DA-SILVA F, CO MM, DESSART C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine[J].Vaccine,2020,38(18):3489-3500.
• [15] López-Fauqued M, CAMPORA L, DELANNOIS F, et al.Safety profile of the adjuvanted recombinant zoster vaccine:Pooled analysis of two large randomised phase 3 trials[J].Vaccine,2019,37(18):2482-2493.
• [16] NELSON JC, Ulloa-Pérez E, YU O, et al. Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data[J].Am J Epidemiol,2023,192(2):205-216.
• [17] BERKOWITZ EM, MOYLE G, STELLBRINK HJ, et al.Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV infected adults:A phase1/2a randomized, placebo-controlled study[J].J Infect Dis,2015,211(8):1279-1287.
• [18] VINK P, DELGADO MINGORANCE I, MAXIMIANO ALONSO C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy:A randomized trial[J].Cancer,2019,125(8):1301-1312.
• [19] BASTIDAS A, DE IA SERNA J, El IDRISSI M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation:A randomized clinical trial[J]. JAMA,2019,322(2):123-133.
• [20] OOSTVOGELS L, HEINEMAN TC, JOHNSON RW, et al.Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted combinant zoster vaccine:Apooled post-hoc analysis of two parallel randomized trials[J].Hum Vaccin Immunother,2019,15(12):2865-2872.
• [21] SATYAM VR, LI PH, REICH J, et al. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease[J].Dig Dis Sci,2020,65(10):2986-2991.
• [22] STEVENS E, WEINBLATT ME, MASSAROTTI E, et al.Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients:A single center′s experience with 400 patients[J].ACR Open Rheumatology,2020,2(6):357-361.
• [23] HIMAL L, CUNNINGHAM A L, OLIVIER G, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults[J].New Engl J Med,2015,372(22):2087-2096.
• [24] SYED YY. Recombinant zoster vaccine(ShingrixR):A review in herpes zoster[J].Drug Aging,2018,35(12):1031-1040.
• [25] ACIP. Grading of recommendations, assessment, development, and evaluation(GRADE):Recombinant zoster vaccine(RZV)and herpes zoster live-attenuated vaccine(ZVL). Atlanta, GA:US Department of Health and Human Services,CDC, Advisory Committee on Immunization Practices[EB/OL].[2020-08-10].https://www.cdc.gov/vaccines/acip/recs/grade/herpes-zoster.html.
• [26]郑东旖,徐娜,金雄渊,等.≥50岁人群带状疱疹减毒活疫苗免疫原性和安全性的随机、双盲、安慰剂对照Ⅱ期临床试验[J].中国疫苗和免疫,2022,28(1):78-82.
• [27] WILLIS ED, WOODWARD M, BROWN E, et al. Herpes zoster vaccine live:A 10 year review of post-marketing safety Experience[J].Vaccine,2017,35(52):7231-7239.
• [28] MBINTA JF, WANG AX, NGUYEN BP, et al. Herpes zoster vaccine safety in the Aotearoa New Zealand population:A self-controlled case series study[J].Nat Commun,2023,14(1):4330.
• [29]张丽娜,李克莉,李燕,等.2020年中国疑似预防接种异常反应监测[J].中国疫苗和免疫,2022,28(2):208-218.
• [30]卜哲妮,孙立梅,赵占杰,等.2020—2021年广东省带状疱疹疫苗疑似预防接种异常反应监测分析[J].华南预防医学,2022,48(5):592-595.
• [31]石凌云,王三凤,原跃礼.2020-2022年河南省焦作市疑似预防接种异常反应监测结果[J].现代疾病预防控制,2023,34(8):587-590.
• [32] HervéC, Laupèze B, DEL GIUDICE G, et al. The how's and what's of vaccine reactogenicity[J].NPJ Vaccines,2019(4):39.
• [33] Laupèze B, HervéC, DI PASQUALE A, et al. Adjuvant systems for vaccines:13 years of post-licensure ex perience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood[J].Vaccine,2019,37(38):5670-5680.
• [34] REN K, DUBNER R. Interactions between the immune and nervous systems in pain[J].Nat Med. 2010,16(11):1267-1276.
• [35] VAN MAELE L, FOUGERON D, CAYET D, et al. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01[J].Eur J Immunol,2019,49(12):2134-2145.
• [36] ANSALDI F, TRUCCHI C, ALICINO C, et al. Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine:A comprehensive review[J].Adv Ther,2016,33(7):1094-1104.
• [37] MORO PL, LEUNG J, MARQUEZ P, et al. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020[J].J Infect Dis,2022,226(S4):S431-S440.
• [38] MORRISON VA, OXMAN MN, LEVIN MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster[J].J Infect Dis,2013,208(4):559-563.
• [39] DROLET M, OXMAN MN, LEVIN MJ, et al. Vaccination against herpes zoster in developed countries:State of the evidence[J].Hum Vaccin Immunother,2013,9(5):1177-1184.